Indazole mGluR4 Allosteric Modulators for Solubility and Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a scarcity of compounds that effectively potentiate mGluR4 receptors for the treatment of neurological and psychiatric disorders associated with glutamatergic neurotransmission dysfunction, and conventional mGluR4 receptor modulators suffer from poor aqueous solubility and oral bioavailability.

Innovation Solution

Development of allosteric modulators, known as receptor allosteric agonist-PAMs, which enhance mGluR4 receptor activity without binding to the orthosteric agonist site, addressing neurological and psychiatric disorders by enhancing glutamatergic tone in specific brain regions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional mGluR4 receptor modulators are used to treat neurological disorders, then they can modulate glutamatergic neurotransmission, but they suffer from poor aqueous solubility and oral bioavailability

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidaqueous solubility and oral bioavailability

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of mGluR4 modulators through systematic variations in molecular composition and configuration. This includes changing functional groups, stereochemistry, and molecular weight parameters to improve aqueous solubility while maintaining pharmacological activity at the receptor level

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by creating hybrid molecular structures that combine pharmacophore elements with solubility-enhancing moieties. These composite molecules integrate the active binding domain with auxiliary groups that improve aqueous solubility and oral bioavailability without compromising receptor affinity

Inventive Principle:

Principle #40Composite materials

2Reliability

If allosteric modulators are developed to enhance mGluR4 activity, then they can provide therapeutic benefits for neurological disorders, but there is currently a scarcity of such compounds with effective potentiation

Engineering Contradiction:

Improvetherapeutic benefitVSAvoidnumber of effective compounds

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies segmentation by dividing the development process into systematic series of compounds with progressively optimized structures. Each series represents a segmented approach to discovering allosteric modulators, allowing methodical exploration of structure-activity relationships to expand the number of effective compounds

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses parameter changes to generate diverse allosteric modulator structures by varying molecular parameters such as functional groups, ring structures, and chain lengths. This systematic parameter variation expands the quantity of compounds with effective potentiation activity

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260070897A1Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publication Date: 2026.03.12 VANDERBILT UNIV

AI summary

Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.